Literature DB >> 22541653

Prediction of proliferative vitreoretinopathy after retinal detachment surgery: potential of biomarker profiling.

Lukas J A G Ricker1, Alfons G H Kessels, Wilco de Jager, Fred Hendrikse, Aize Kijlstra, Ellen C la Heij.   

Abstract

PURPOSE: To investigate the potential of a combined assessment of clinical risk factors and biomarker profiling in the prediction of proliferative vitreoretinopathy (PVR) after retinal detachment surgery.
DESIGN: Retrospective case-control study.
METHODS: Multiplex bead-based immunoassays were used for the simultaneous measurement of 50 biomarkers in subretinal fluid samples obtained from patients who underwent scleral buckling surgery for primary rhegmatogenous retinal detachment (RRD). Of 306 samples that were collected and stored in our BioBank, we selected 21 samples from patients in whom a redetachment developed as a result of PVR within 3 months after reattachment surgery for primary RRD (PVR group). These were compared with age-, sex-, and storage time-matched RRD samples from 54 patients with an uncomplicated postoperative course after primary RRD repair (RRD group).
RESULTS: Preoperative PVR was the only clinical variable that was an independent predictor of postoperative PVR development (P = .035) and resulted in an area under the receiver operating characteristic curve of 0.67 (95% confidence interval, 0.51 to 0.83). The addition of the biomarkers chemokine (C-C motif) ligand 22, interleukin-3, and macrophage migration inhibitory factor improved the model significantly (P < .001) and resulted in an area under the receiver operating characteristic curve of 0.93 (95% confidence interval, 0.82 to 1.04). A sensitivity of 94.1% and a specificity of 94.2% were reached, using a cutoff value of 5%.
CONCLUSIONS: In combination with preoperative PVR grade, the measurement of a single biomarker or a small multibiomarker panel shows great potential and may predict postoperative PVR development after primary RRD in a highly sensitive and specific manner.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541653     DOI: 10.1016/j.ajo.2012.02.004

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  12 in total

1.  The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment.

Authors:  Yong Wei; RongLe Zhou; Xiaobo Wang; Xiuju Chen; Hao Chen
Journal:  Eye (Lond)       Date:  2019-04-02       Impact factor: 3.775

Review 2.  Proliferative Vitreoretinopathy: A Review.

Authors:  Sana Idrees; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2019

Review 3.  Minireview: Fibronectin in retinal disease.

Authors:  Charles G Miller; Greg Budoff; Jonathan L Prenner; Jean E Schwarzbauer
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-20

4.  Proliferative vitreoretinopathy and genetic profile.

Authors:  Khalil Ghasemi Falavarjani
Journal:  J Ophthalmic Vis Res       Date:  2013-01

5.  Identification of inflammatory mediators in patients with rhegmatogenous retinal detachment associated with choroidal detachment.

Authors:  Ying Dai; Zhifeng Wu; Huiming Sheng; Zhengwei Zhang; Mengxi Yu; Qing Zhang
Journal:  Mol Vis       Date:  2015-04-10       Impact factor: 2.367

6.  Amino acid and vascular endothelial growth factor levels in subretinal fluid in rhegmatogenous retinal detachment.

Authors:  Ozgur Yalcinbayir; Rifat Levent Buyukuysal; Oner Gelisken; Cagatay Buyukuysal; Basak Can
Journal:  Mol Vis       Date:  2014-09-21       Impact factor: 2.367

Review 7.  Preoperative, Intraoperative and Postoperative Corticosteroid Use as an Adjunctive Treatment for Rhegmatogenous Retinal Detachment.

Authors:  Vincenza Bonfiglio; Michele Reibaldi; Iacopo Macchi; Matteo Fallico; Corrado Pizzo; Clara Patane; Andrea Russo; Antonio Longo; Alessandra Pizzo; Giovanni Cillino; Salvatore Cillino; Maria Vadalà; Michele Rinaldi; Robert Rejdak; Katarzyna Nowomiejska; Mario Damiano Toro; Teresio Avitabile; Elina Ortisi
Journal:  J Clin Med       Date:  2020-05-21       Impact factor: 4.241

8.  Proliferative vitreoretinopathy: current and emerging treatments.

Authors:  Ama Sadaka; Gian Paolo Giuliari
Journal:  Clin Ophthalmol       Date:  2012-08-14

9.  Expression of VEGF-A, Otx homeobox and p53 family genes in proliferative vitreoretinopathy.

Authors:  Claudio Azzolini; Ilaria Stefania Pagani; Cristina Pirrone; Davide Borroni; Simone Donati; Muna Al Oum; Diana Pigni; Anna Maria Chiaravalli; Riccardo Vinciguerra; Francesca Simonelli; Giovanni Porta
Journal:  Mediators Inflamm       Date:  2013-10-21       Impact factor: 4.711

Review 10.  Inflammatory and Fibrogenic Factors in Proliferative Vitreoretinopathy Development.

Authors:  Rishika Chaudhary; Robert A H Scott; Graham Wallace; Martin Berry; Ann Logan; Richard J Blanch
Journal:  Transl Vis Sci Technol       Date:  2020-02-21       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.